*Laboratorio de Fisiología de los Procesos Inflamatorios, Instituto de Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Pacheco de Melo 3081, C1425AUM, Buenos Aires, Argentina.
Clin Sci (Lond). 2014 Mar;126(5):355-65. doi: 10.1042/CS20130236.
Secondary infections due to post-sepsis immunosuppression are a major cause of death in patients with sepsis. Strategies aimed at restoring immune functions offer a new perspective in the treatment of sepsis. In the present study, we used LPS (lipopolysaccharide)-immunosuppressed mice to analyse the effects of ATRA (all-trans retinoic acid) on different immune parameters. The IS (immunocompromised) group had decreased lymphocyte and increased MDSC (myeloid-derived suppressor cell) counts in lymph nodes. They also had an impaired in vitro T-cell proliferation, mediated by MDSCs. ATRA administration restored T-cell proliferation, which was associated with a decreased number of live MDSCs. The IS group treated with ATRA had an increased number of CD4+ and CD8+ T-cells. ATRA partially improved the primary humoral immune response, even when immunosuppression was established first and ATRA was administered subsequently. Our results demonstrate that ATRA restores immunocompetence by modulating the number of leucocytes and the survival of MDSCs, and thus represents an additional potential strategy in the treatment of the immunosuppressive state of sepsis.
继发于脓毒症后免疫抑制的感染是导致脓毒症患者死亡的主要原因。旨在恢复免疫功能的策略为脓毒症的治疗提供了新视角。在本研究中,我们使用 LPS(脂多糖)免疫抑制小鼠来分析 ATRA(全反式视黄酸)对不同免疫参数的影响。IS(免疫功能低下)组的淋巴结中淋巴细胞减少,MDSC(髓源抑制细胞)增加。它们的体外 T 细胞增殖也受到 MDSC 的损害。ATRA 给药恢复了 T 细胞增殖,这与活 MDSC 数量减少有关。用 ATRA 治疗的 IS 组 CD4+和 CD8+T 细胞数量增加。ATRA 部分改善了原发性体液免疫应答,即使在首先建立免疫抑制并随后给予 ATRA 的情况下也是如此。我们的结果表明,ATRA 通过调节白细胞数量和 MDSC 的存活来恢复免疫能力,因此代表了治疗脓毒症免疫抑制状态的另一种潜在策略。